Promoting Effects of the Adipokine, Apelin, on Diabetic Nephropathy

@article{Zhang2013PromotingEO,
  title={Promoting Effects of the Adipokine, Apelin, on Diabetic Nephropathy},
  author={Bao-hai Zhang and Wenying Wang and Hongxia Wang and Jiming Yin and Xiang-jun Zeng},
  journal={PLoS ONE},
  year={2013},
  volume={8}
}
Angiogenesis, increased glomerular permeability, and albuminuria are thought to contribute to the progression of diabetic nephropathy (DN). Apelin receptor (APLNR) and the endogenous ligand of APLNR, apelin, induce the sprouting of endothelial cells in an autocrine or paracrine manner, which may be one of the mechanisms of DN. The aim of this study was to investigate the role of apelin in the pathogenesis of DN. Therefore, we observed apelin/APLNR expression in kidneys from patients with type 2… Expand
Apelin promotes diabetic nephropathy by inducing podocyte dysfunction via inhibiting proteasome activities
TLDR
The results suggest that apelin induces podocyte dysfunction in DN through ER stress which was induced by decreased proteasome activities in podocytes. Expand
Application of Apelin-13 to treatment of diabetic nephropathy
TLDR
Apelin-13 can be used a medicine for treating diabetic nephropathy by taking the reduction of the acetylation of histones as a target. Expand
The relationship between serum apelin level and different grades of diabetic nephropathy in type 2 diabetic patients
TLDR
Serum APLN is significantly higher in patients with DN compared with diabetic patients without nephropathy, and there is a positive correlation between serum apelin and the degree of DN, suggesting that APlN may play an important role in the development of DN. Expand
Apelin impairs myogenic response to induce diabetic nephropathy in mice
TLDR
Increased apelin concentration in serum of diabetic mice neutralized the myogenic response mediated by apelin receptor (APJ) and resulted in increased RBF, which promoted the progression of diabetic nephropathy. Expand
Apelin: A novel inhibitor of vascular calcification in chronic kidney disease.
TLDR
Exogenous supplementation of apelin-13 normalized the level of the apelin/APJ system and significantly ameliorated aortic calcification, as well as the suppression of Runx2, OPG and Pit-1 expression, suggesting apelin may have potential therapeutic value for treatment of VC in CKD. Expand
The Role of Apelin 13 in Progression of Chronic Kidney Disease.
TLDR
This study was the first that clinically examined the relationship between apelin 13 and CKD progression and found that several factors causing comorbidity and progression may have probably masked this potential relationship. Expand
Evaluation of adipocytokines in children with chronic kidney disease.
TLDR
Changes in serum adipocytokines concentration are associated with the kidney dysfunction in CKD in children and longitudinal studies on larger groups of paediatric cohorts would enable further understanding of the risk factors for CKD progression. Expand
Elevation of serum apelin-13 associated with proliferative diabetic retinopathy in type 2 diabetic patients.
TLDR
A positive association of apelin-13 serum level with PDR is elucidated, which may influence the promotion of PDR but unrelated with VEGF, as well as other variables, including age, duration of diabetes, blood pressure, CRP, HbA1c and total-cholesterol. Expand
Apelin/APJ system: A novel therapeutic target for oxidative stress-related inflammatory diseases (Review).
TLDR
This review summarizes the association between apelin/APJ, oxidative stress and inflammation-related diseases and recommends drugs targeting the apelin /APJ system as a novel therapeutic strategy for oxidative stress-related inflammatory diseases. Expand
Apelin/APJ system as a therapeutic target in diabetes and its complications.
TLDR
The role of apelin/APJ system is highlighted as a novel therapeutic target for pharmacological intervention in treating diabetes and its complications through agonists and antagonists targeted to APJ receptor. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 44 REFERENCES
Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy.
TLDR
Current research has focused on the podocyte as a central target for the effects of the metabolic milieu in the development and progression of diabetic albuminuria, and pathophysiological changes in the ultrafiltration barrier lead to an increased tubular filtration of various growth factors that may further alter the function of tubular cells. Expand
Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy.
TLDR
The potential use of antiangiogenic tumstatin peptide as a novel therapeutic agent in early diabetic nephropathy is demonstrated and is demonstrated to be similar to that of angiogenesis. Expand
Apelin-13 passes through the ADMA-damaged endothelial barrier and acts on vascular smooth muscle cells
TLDR
It is suggested that ADMA increases endothelial permeability, which may involve the p38 MAPK and NADPH oxidase pathway. Expand
Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice.
TLDR
The effect of PIO on microalbuminuria might not be due to changing systemic blood pressure and blood glucose levels, and it appears that the decrease of urinary albumin excretion might be related to improvement of glomerular enlargement, including hyperfiltration, since the levels of ecNOS protein were reduced by PIO in the glomersular vessels. Expand
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy.
TLDR
It is proposed that activation of RAGE contributes to expression of VEGF and enhanced attraction/activation of inflammatory cells in the diabetic glomerulus, thereby setting the stage for mesangial activation and TGF-beta production; processes which converge to cause albuminuria and glomerulosclerosis. Expand
Apelin is a novel angiogenic factor in retinal endothelial cells.
There has been much focus recently on the possible functions of apelin, an endogenous ligand for the orphan G-protein-coupled receptor APJ, in cardiovascular and central nervous systems. We report aExpand
Neovascularization at the vascular pole region in diabetic glomerulopathy.
  • R. Osterby, J. Asplund, +4 authors J. Walker
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 1999
TLDR
The vascular abnormality localized to the vascular pole region is observed occasionally in the normal kidney, but the frequency is increased in patients with diabetic glomerulopathy, which might lead to less pronounced elevation of albumin excretion. Expand
Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man.
TLDR
Diabetic nephropathy is associated with glomerular capillary rarefaction, and the decreased receptor-bound VEGF on the endothelium may be an indicator of an insufficient capillary repair reaction. Expand
Endothelial dysfunction : Mechanisms of hypertension: Cells, hormones, and the kidney
TLDR
Mechanisms that participate in the reduced vasodilatory responses in endothelial dysfunction include reduced nitric oxide generation, oxidative excess, and reduced production of hyper-polarizing factor. Expand
Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.
TLDR
Inhibition of eNO predisposes mice to classic diabetic nephropathy, likely due to VEGF-NO uncoupling with excessive endothelial cell proliferation coupled with altered autoregulation consequent to the development of preglomerular arteriolar disease. Expand
...
1
2
3
4
5
...